Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia.

Leukemia - 1 Jul 2020

Yan Bowen, Chen Qinwei, Xu Jianfeng, Li Wei, Xu Bing, Qiu Yi

Abstract excerpt

TP53 mutations (TP53mut) in AML patients associate with poor prognosis that may affect therapy and outcome. In addition to TP53 mut patients, TCGA AML patient sequencing data show that there are around 3% of patients have detectable low-frequency TP53mut reads. Importantly, these patients showed worse outcome as compared with the TP53 wild type (TP53wt) patients. We have studied the effect of low-frequency...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Antibiotics, Antineoplastic
Share to Depsipeptides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histone Deacetylase Inhibitors

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Mutation Rate

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 31988438
DOI: 10.1038/s41375-020-0710-7
PMCID: PMC7597970

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia.PMID 31988438Read ↗

AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.Semantic proximity Read ↗

TP53 Mutation in Acute Myeloid Leukemia: An Old Foe RevisitedSemantic proximity Read ↗

The Role Of Early TP53 Mutations On The Evolution Of Therapy-Related AMLSemantic proximity Read ↗

Development of TP53 mutations over the course of therapy for acute myeloid leukemia.Semantic proximity Read ↗

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation.Semantic proximity Read ↗

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.Semantic proximity Read ↗

TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.Semantic proximity Read ↗

Clinical and Molecular Characterization of p53-Mutated Acute Myeloid LeukemiaSemantic proximity Read ↗

<i>TP53</i> mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomesSemantic proximity Read ↗

Detection of TP53 Mutation in Acute Myeloid Leukemia by RT-PCR-Based Sanger Sequencing.Semantic proximity Read ↗

Loss of p53 enhances the tumor-initiating potential and drug resistance of clonogenic multiple myeloma cellsSemantic proximity Read ↗

Somatic TP53 Mutations Drive T and NK Cell Dysfunction in AML and Can be Rescued by Reactivating Wild Type p53Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.